Creo Medical announced plans to sell its remaining 49% stake in its European division to the division's CEO, with the deal expected to complete within three months pending approvals. The company also plans to raise approximately £5.5 million through a share placing at a 31.9% premium, with directors and the Development Bank of Wales subscribing significant amounts. Full-year 2025 results showed strong revenue growth and reduced losses, and the company expects 2026 revenue growth between 50% and 60%. The stake sale and fundraising aim to simplify the group, strengthen the balance sheet, and fund the company until it reaches sustainable cash flow and profitability.
Last week, large-cap stocks in sectors like technology, electric vehicles, data centers, and healthcare experienced declines due to weak earnings guidance, regulatory worries, rising bond yields, and increased competition. Notable losers included Int...
Ethereum's price remains stable around $2,000 while it controls 55% of tokenized assets and 51% of DeFi value locked globally. Over 39.1 million ETH are staked, with 3.49 million more queued for validation, tightening supply despite price pressure. I...
Taiwan Semiconductor Manufacturing Company (TSMC) dominates the pure foundry market with a 72% share and produces nearly 99% of AI ASICs for major hyperscalers, positioning it for durable, profitable growth driven by AI demand. The company is expandi...
Sandisk secured $42 billion in contractual obligations, covering over one-third of its FY27 bit volume with financial guarantees. In Q3, the company posted a non-GAAP gross margin of 78.4%, up from 51.1%, and revenue of $5.95 billion, exceeding guida...
The USD stablecoin USDR lost 37% of its value following a $10 million governance exploit at its issuer, StablR. The hacker gained control by exploiting a weak administrative key system, minted millions of USDR and EURR tokens without real backing, an...
